The Treatment Was Promising. The Evidence Wasn’t Enough.

A number can make a drug company look inevitable. In Lykos Therapeutics’ second Phase 3 trial, 71.2% of participants who received MDMA with therapy no longer met diagnostic criteria for PTSD at the study endpoint. The corresponding figure for those who received placebo with therapy was 47.6%. Read those two numbers quickly and the ending appears written. Read the FDA’s later letter and the ending changes.

This is the peculiar Lykos story: a company built to bring an unconventional therapy into conventional medicine, undone at its first approval attempt by questions that conventional medicine asks of every drug. The questions were pointed. Which effects were recorded? How long did improvement last? Could patients and therapists tell who received the active drug? And how much of the benefit belonged to the medicine, rather than to the unusually intensive therapy delivered beside it?

A nonprofit’s drug company

The Multidisciplinary Association for Psychedelic Studies, or MAPS, founded the company in 2014 as MAPS Public Benefit Corporation. MAPS itself had spent decades supporting psychedelic research. Its subsidiary had a more specific assignment: move an investigational treatment through trials, regulation and, if approved, into healthcare. The proposed product was midomafetamine, the pharmaceutical name for MDMA, administered with psychological support to adults with post-traumatic stress disorder.

In the research protocol, the drug was only one part of the treatment. Patients received preparation, three supervised medication sessions, and integration sessions afterward. That made Lykos unusual among drug developers. It was trying to bring a pill to market, but the pill’s promise depended on a trained human being, a long appointment, and a clinical setting able to keep patients safe. Its intended customers were therefore healthcare systems, qualified prescribers and therapists serving eligible PTSD patients. There was no approved product to sell directly to patients.

In January 2024, the company took the name Lykos and announced an oversubscribed Series A of more than $100 million, led by Helena. The money marked a change in its economics. Philanthropy had helped carry MAPS’s research; investors would help build the machinery for a possible launch. That machinery meant more than manufacturing capsules. Lykos planned clinician education, patient monitoring and arrangements with facilities that could deliver this labor-heavy form of care. It was an expensive bet whose precise total development cost is not public. The reported financing gives a floor for the scale of the wager, not a price tag for the whole program.

The number that traveled farther than the caveats

Lykos’s studies were substantial achievements. The first Phase 3 trial was published in 2021, the second in 2023. In the latter, 37 of 52 participants in the MDMA-assisted therapy group no longer met PTSD criteria by the study’s end, compared with 20 of 42 in the placebo-and-therapy group. For people living with a chronic disorder, those results demanded serious attention. They did not, however, answer every question required for approval.

The trial design contained a stubborn problem familiar to psychedelic researchers: an active drug with noticeable effects is hard to disguise as a placebo. If participants can guess which group they are in, expectations can influence outcomes. Lykos also enrolled many people with prior MDMA experience. In its complete response letter, the FDA said roughly 40% of enrolled participants reported previous use, raising a concern that this sample might not represent the broader PTSD population and could be especially prone to guessing its assignment.

The agency’s other objection was more prosaic and more damaging. It said trial training materials told sites not to record “positive” or “favorable” experiences as adverse events, even though such experiences could signal abuse potential or impairment. Inspections also found unreported adverse events at two sites. A clinical team may hear the word positive and think good. A regulator examining a psychoactive drug may hear it and ask whether the experience could encourage misuse. The same adjective changes meaning when the job changes.

“We cannot approve this application in its present form.”FDA complete response letter, August 2024

Then there was time. PTSD is chronic; Lykos’s main study endpoint came 18 weeks after treatment began, about eight weeks after the last drug session. The FDA said the follow-up data did not establish how durable the benefit was or whether another treatment cycle might be needed. For a therapy intended to be given only a few times, that is not a footnote. It is part of the product instructions a doctor would need.

The launch plan meets the letter

The FDA’s advisory committee voted against the application in June 2024. In August, the agency declined approval and suggested a new randomized trial with longer blinded follow-up, stronger safety capture and steps to reduce bias. It also encouraged an independent audit of trial records, including session recordings, to look for missed adverse events. Concerns about therapist conduct had already made oversight especially consequential. Lykos had announced plans for an independent advisory board and certified treatment facilities, but those plans could not repair data that had not been collected in the original studies.

The setback hit the business immediately. Lykos cut staff, changed leadership and turned its attention from launch preparation to answering the regulator. In May 2025 it announced the first close of a $50 million Series B recapitalization. Later that year it took another name, Resilient Pharmaceuticals. MAPS, the nonprofit that founded and funded the earlier research, says it now has no active role in the company’s drug-development program. In August 2026 MAPS responded to reporting that Resilient had resubmitted the MDMA application. A resubmission is another review, not an approval.

The part others can copy

Lykos still matters to the market because it exposed where a new class of treatment meets the old machinery of evidence. Its closest alternatives for patients are established PTSD treatments, including trauma-focused psychotherapy and approved medicines. Other psychedelic companies pursue different compounds and conditions. Lykos’s distinguishing wager was the full package: drug, therapist training, supervised setting and a proposed safety system. That package may be clinically meaningful; it is also harder to study, staff, reimburse and regulate than a pill taken at home.

For another developer, the transferable lesson is practical. Decide before a pivotal trial how to capture every relevant effect, including pleasant ones. Measure expectation and blinding. Plan long-term follow-up for a chronic condition. Make therapist conduct and treatment consistency auditable. Ask whether the care model can fit real clinics and payers. These steps will not make a therapy effective, and they will not make a costly session easy to deliver. They do make the evidence harder to dismiss.

The Lykos case is often told as a fight between a promising medicine and cautious regulators. The documents tell a sharper story. Promising results created the reason to run the experiment. Approval required the company to show that the result would survive a closer look. That distinction cost Lykos its first launch, much of its workforce and even its name. It may yet prove the treatment. But the bar it met in a headline was never the only bar.